Review of first year result of photodynamic therapy on age-related macular degeneration in chinese population

Eye

Volumn 20, Issue 5, 2006, Pages 523-526

  Yang, N ^a   Fan, C M ^a   Ho, C K ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; CASE STUDY; CAUCASIAN; CHINESE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; PHOTODYNAMIC THERAPY; RACE DIFFERENCE; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISCRIMINATION; VISUAL SYSTEM EXAMINATION;

EID: 33646417971     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6701991     Document Type: Review

References (19)

1. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES et al. Photodynamic therapy with verteporfin for CNV caused by aged-related macular degeneration. Results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1177-1187.
2. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I et al. Photodynamic therapy with verteporfin for CNV caused by aged- related macular degeneration. Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1161-1173.
3. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal CNV in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trial - TAP report 1. Arch Ophthalmol 1999; 117: 1329-1345.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal CNV in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trial - TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
5. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of aged related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993; 111: 1200-1209.
6. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of aged related macular degeneration. Arch Ophthalmol 1991; 109: 1220-1231.
7. Brown GC, Brown MM, Sharma S. Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology 2000; 107: 1374-1380.
8. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001; 108: 841-852.
9. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
10. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 5. Arch Ophthalmol 2003; 120: 1307-1314.
11. Fine S. Photodynamic therapy with verteporfin is effective for selective patients with neovascular age-related macular degeneration. Arch Ophthalmol 1999; 177: 1400-1402.
12. Wu L, Murphy RP. Photodynamic therapy: A new approach to the treatment of choroidal neovascularization secondary to age-related macular degeneration. Curr Opin Ophthalmol 1999; 10: 217-220.
13. American Academy of Ophthalmology. Photodynamic therapy with verteporfin for age-related macular degeneration. Ophthalmology 2000; 107: 2314-2317.
14. Soubrane G, Bressler N. Treatment of subfoveal choroidal neovascularization in age-related macular degeneration: Focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol 2001; 85: 483-495.
15. Husain D, Kramer M, Kenny A. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroids up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999; 40: 2322-2331.
16. Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streak, and idiopathic causes. Arch Ophthalmol 2000; 117: 327-336.
17. Lim J, Kwok A, Wilson D. Symptomatic age-related macular degeneration in Asian patients. Retina 1998; 18: 435-438.
18. Pieramici D, Bressler N, Bressler S. Choroidal neovascularization in black patients. Arch Ophthalmol 1994; 112: 1043-1046.
19. Verteporfin Roundtable 2000 and 2001. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22: 6-18.